Gerry Castillo
Technik-/Wissenschafts-/F&E-Leiter bei PharmaIN Corp.
Profil
Gerry Castillo is currently the Director of Research & Intellectual Property at PharmaIN Corp.
Previously, he worked as the Biochemistry Director at ProteoTech, Inc. Castillo holds a doctorate degree from the University of Toronto, an undergraduate degree from the University of Saskatchewan, and a graduate degree from the University of Windsor.
Aktive Positionen von Gerry Castillo
| Unternehmen | Position | Beginn |
|---|---|---|
PharmaIN Corp.
 PharmaIN Corp. Pharmaceuticals: MajorHealth Technology PharmaIN Corp. develops affinity-based drug delivery solutions for biotech and pharmaceutical applications. It develops drug therapies using its proprietary, novel drug delivery platform called Protected Graft Co-polymer. The company was founded by Elijah M. Bolotin in 2000 and is headquartered in Bothell, WA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Gerry Castillo
| Unternehmen | Position | Ende |
|---|---|---|
ProteoTech, Inc.
 ProteoTech, Inc. Medical/Nursing ServicesHealth Services ProteoTech, Inc. operates as a private drug development company. It focuses on targeting amyloid diseases. The firm is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes, and systemic amyloidosis. The company was founded in 1996 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Ausbildung von Gerry Castillo
| University of Saskatchewan | Undergraduate Degree |
| University of Windsor | Graduate Degree |
| University of Toronto | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
PharmaIN Corp.
PharmaIN Corp. Pharmaceuticals: MajorHealth Technology PharmaIN Corp. develops affinity-based drug delivery solutions for biotech and pharmaceutical applications. It develops drug therapies using its proprietary, novel drug delivery platform called Protected Graft Co-polymer. The company was founded by Elijah M. Bolotin in 2000 and is headquartered in Bothell, WA. | Health Technology |
ProteoTech, Inc.
ProteoTech, Inc. Medical/Nursing ServicesHealth Services ProteoTech, Inc. operates as a private drug development company. It focuses on targeting amyloid diseases. The firm is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes, and systemic amyloidosis. The company was founded in 1996 and is headquartered in Seattle, WA. | Health Services |
